Jasper Therapeutics(JSPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

JSPR Jasper Therapeutics

Market Closed 04-17 16:00:00 EDT

1.02

+0.05

+5.60%

盘后1.05

+0.03+2.81%

19:49 EDT

High1.05	Low0.9613	Vol457.20K
Open1.00	D1 Closing0.9659	Amplitude9.18%
Mkt Cap28.54M	Tradable Cap23.27M	Total Shares27.98M
T/O464.77K	T/O Rate2.00%	Tradable Shares22.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"JSPR","market":"US","secType":"STK","nameCN":"Jasper Therapeutics","latestPrice":1.02,"timestamp":1776456000000,"preClose":0.9659,"halted":0,"volume":457199,"hourTrading":{"tag":"盘后","latestPrice":1.0487,"preClose":1.02,"latestTime":"19:49 EDT","volume":1523,"amount":1581.8507,"timestamp":1776469778210,"change":0.0287,"changeRate":0.028137,"amplitude":0.028137},"delay":0,"changeRate":0.0560099389170722,"floatShares":22810300,"shares":27984039,"eps":-3.954536,"marketStatus":"Market Closed","change":0.0541,"latestTime":"04-17 16:00:00 EDT","open":1,"high":1.05,"low":0.9613,"amount":464766.3292485,"amplitude":0.091831,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.954536,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776672000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.9659,"preHourTrading":{"tag":"盘前","latestPrice":0.9852,"preClose":0.9659,"latestTime":"07:17 EDT","volume":2,"amount":1.9704,"timestamp":1776424670607,"change":0.0193,"changeRate":0.019981,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.0487,"preClose":1.02,"latestTime":"19:49 EDT","volume":1523,"amount":1581.8507,"timestamp":1776469778210,"change":0.0287,"changeRate":0.028137,"amplitude":0.028137},"volumeRatio":0.75763953035128,"impliedVol":0.5694,"impliedVolPercentile":0.132},"requestUrl":"/m/hq/s/JSPR","defaultTab":"news","newsList":[{"id":"2624543387","title":"Jasper Therapeutics Is Maintained at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2624543387","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624543387?lang=en_us&edition=fundamental","pubTime":"2026-04-02 01:16","pubTimestamp":1775063760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/JSPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2026 13:16 ET (17:16 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624513313","title":"Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2624513313","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624513313?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:59","pubTimestamp":1775044780,"startTime":"0","endTime":"0","summary":"Evercore ISI lowered the firm’s price target on Jasper Therapeutics (JSPR) to $7 from $12 and keeps an Outperform rating on the shares. The firm ad...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-price-target-lowered-to-7-from-12-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-price-target-lowered-to-7-from-12-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623216833","title":"Jasper Therapeutics Q4 EPS $(0.32) Beats $(0.64) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623216833","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623216833?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:53","pubTimestamp":1774904023,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.64) by 50.31 percent. This is a 80.25 percent increase over losses of $(1.62) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51553686/jasper-therapeutics-q4-eps-0-32-beats-0-64-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Jasper Therapeutics Q4 EPS $(0.32) Beats $(0.64) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623218943","title":"Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623218943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623218943?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:37","pubTimestamp":1774903033,"startTime":"0","endTime":"0","summary":"“Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthm...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-reports-q4-eps-32c-consensus-82c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-reports-q4-eps-32c-consensus-82c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623329427","title":"Jasper Therapeutics Q4 EPS USD -0.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2623329427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623329427?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:32","pubTimestamp":1774902731,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nPLXE0F294:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JSPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623932949","title":"Jasper Therapeutics FY25 net loss narrows to $75.8 million; cash drops to $28.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623932949","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623932949?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:30","pubTimestamp":1774902656,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics posted Q4 net loss of USD 9.1 million, narrowing from a year earlier, while full-year net loss widened to USD 75.8 million.Operating loss totaled USD 15.8 million for the quarter, improving from the prior-year period.Cash and cash equivalents fell to USD 28.7 million at Dec. 31, 2025.Briquilimab showed updated CSU data with 67% complete response at 12 weeks in BEACON Cohort 9.1, while 75% achieved complete response or well-controlled disease at 12 weeks in the open-label extension.Management said it remains on track to start enrolling patients in a Phase 2b/3 CSU study in the second half of 2026, pending capital availability.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL1ry4Bg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4112","SG9999014005.SGD","SG9999014039.USD","BK4139","BK4585","LU2210150020.SGD","JSPR","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623532944","title":"Press Release: Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623532944","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623532944?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:30","pubTimestamp":1774902600,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., March 30, 2026  -- Jasper Therapeutics, Inc.  , a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit  to address mast cell driven diseases such as chronic spontaneous urticaria , chronic inducible urticaria  and asthma, today reported results for the fiscal quarter and year ended December 31, 2025 and provided a corporate update.\"Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma,\" said Jeet Mahal, President and Chief Executive Officer of Jasper. \"We are very pleased with the chronic urticaria data we reported in January from the BEACON study as well the open-label extension study, which reaffirmed the potential of briquilimab to drive rapid and durable disease control in patients. We are finalizing dose selection for the Phase 2b portion of our planned Phase 2b/3 study in CSU where we will evaluate two ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621707892","title":"Jasper Therapeutics Inc : UBS Assumes Coverage With Neutral Rating; Target Price $1.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2621707892","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621707892?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:07","pubTimestamp":1774278465,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0TH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JSPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770248","title":"UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770248","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770248?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:58","pubTimestamp":1774277906,"startTime":"0","endTime":"0","summary":"Price: 1.18, Change: -0.05, Percent Change: -4.47","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621706973","title":"Jasper Therapeutics Coverage Assumed by UBS at Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706973","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706973?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:01","pubTimestamp":1774270860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/JSPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 09:01 ET (13:01 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616337023","title":"Jasper Therapeutics Inc. Publishes Corporate Presentation on Briquilimab Mast Cell Depletion Programs in Chronic Urticaria and Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2616337023","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616337023?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:32","pubTimestamp":1772458340,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. Publishes Corporate Presentation on Briquilimab Mast Cell Depletion Programs in Chronic Urticaria and Asthma. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL5zRxyY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614723131","title":"Jasper Therapeutics to Present at TD Cowen Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2614723131","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614723131?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:31","pubTimestamp":1771968668,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics to Present at TD Cowen Healthcare Conference               Jasper Therapeutics Inc. will participate in the 46th Annual TD Cowen Healthcare Conference in Boston, Massachusetts, hel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDLbRXRqb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2095319765.USD","BK4588","BK4139","IE00BKPKM429.USD","IE00BGHQF748.EUR","NDAQ","IE00B64PRP62.GBP","SG9999014021.USD","LU2210150020.SGD","BK4585","JSPR","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014005.SGD","LU0314104364.USD","SG9999014013.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613782094","title":"Jasper Therapeutics Inc  expected to post a loss of 67 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2613782094","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613782094?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:36","pubTimestamp":1771853768,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc  expected to post a loss of67cents a share - Earnings Preview Jasper Therapeutics Inc JSPR.OQ JSPR.O is expected to  show no change in quarterly revenue when it reports  result","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL8N3ZJ16O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603305996","title":"Jasper Therapeutics initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2603305996","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603305996?lang=en_us&edition=fundamental","pubTime":"2026-01-14 04:20","pubTimestamp":1768335615,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw analyst Mike King initiated coverage of Jasper Therapeutics (JSPR) with a Buy rating and $17 price target Published first on TheFl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JSPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603542792","title":"Jasper Therapeutics Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2603542792","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603542792?lang=en_us&edition=fundamental","pubTime":"2026-01-13 01:02","pubTimestamp":1768237364,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. provided an update on its lead investigational drug, briquilimab, highlighting its targeted mast cell depletion capabilities in multiple inflammatory diseases, including chronic urticaria and asthma. The presentation details briquilimab’s mechanism of action, which involves direct, high-affinity blockade of the KIT receptor, leading to rapid and durable clinical responses. Clinical data from over 95 patients across multiple studies, including BEACON, SPOTLIGHT, and OLE, demonstrated significant reductions in disease activity scores and a favorable safety profile, with most adverse events being mild and transient. The results support the initiation of a Phase 2b study in chronic spontaneous urticaria, planned to enroll 75-100 patients to further evaluate two dosing regimens against placebo. Briquilimab remains an investigational drug and is not approved for any indication. You can access the full presentation through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL96YnJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602512394","title":"Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512394","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512394?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:55","pubTimestamp":1767894936,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Jasper Therapeutics and keeping the price target at $20.00. Emily Bodnar’s rat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/briquilimabs-robust-efficacy-and-favorable-safety-in-urticaria-indicate-strong-upside-for-jasper-therapeutics-and-support-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/briquilimabs-robust-efficacy-and-favorable-safety-in-urticaria-indicate-strong-upside-for-jasper-therapeutics-and-support-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601366198","title":"Jasper Therapeutics Reports Positive Updated Data From Briquilimab Studies in Chronic Spontaneous Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366198?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873650,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y81P2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601366414","title":"Jasper Therapeutics Reports Positive Briquilimab Data in Chronic Spontaneous Urticaria Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366414","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366414?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873615,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. announced positive updated clinical data from its BEACON Phase 1b/2a study and open label extension study evaluating briquilimab, a novel antibody therapy targeting KIT , in patients with chronic spontaneous urticaria  and chronic inducible urticaria . In the BEACON study, 83% of participants in the 240mg/180mg Q8W cohort achieved a complete response by week 3 after the initial dose, and 67% achieved a complete response at 12 weeks. In the open label extension study, 58% of CSU participants achieved a complete response at 12 weeks, and 75% achieved complete response or well controlled disease. KIT-related adverse events were low in frequency and predominantly low-grade. Jasper Therapeutics stated that these results provide sufficient data to inform dose selection for a planned Phase 2b study in CSU expected to begin in the second half of 2026. The company presented these results in a conference call and webinar, with presentation slides and webcast available on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL75m7Lh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4139","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00B64PRP62.GBP","BK4588","JSPR","LU0314104364.USD","LU2095319765.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601038498","title":"BRIEF-Jasper Therapeutics Appoints Jeet Mahal As Chief Executive Officer To Lead Next Phase Of Clinical Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2601038498","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601038498?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:19","pubTimestamp":1767824363,"startTime":"0","endTime":"0","summary":"BRIEF-Jasper Therapeutics Appoints Jeet Mahal As Chief Executive Officer To Lead Next Phase Of Clinical GrowthJan 8 (Reuters) - Jasper Therapeutics Inc JSPR.O:JASPER THERAPEUTICS APPOINTS JEET MAHAL A","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUAJ5FFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601389746","title":"Jasper Therapeutics Names Jeet Mahal CEO and Thomas Wiggans Executive Chairperson","url":"https://stock-news.laohu8.com/highlight/detail?id=2601389746","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601389746?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:30","pubTimestamp":1767821409,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. has appointed Jeet Mahal as President and Chief Executive Officer, effective January 5, 2026. Thomas Wiggans, previously Chairperson of the Board, has been named Executive Chairperson. Jeet Mahal also joins the company's Board of Directors. Ronald Martell is stepping down as CEO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL8gJ0vq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014021.USD","BK4112","BK4585","IE00BKPKM429.USD","LU2095319765.USD","BK4139","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","SG9999014039.USD","JSPR","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jaspertherapeutics.com","stockEarnings":[{"period":"1week","weight":0.2713},{"period":"1month","weight":-0.1639},{"period":"3month","weight":-0.3333},{"period":"6month","weight":-0.5837},{"period":"1year","weight":-0.7431},{"period":"ytd","weight":-0.4426}],"compareEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.0736},{"period":"3month","weight":0.0267},{"period":"6month","weight":0.0689},{"period":"1year","weight":0.349},{"period":"ytd","weight":0.0414}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.285776},{"month":2,"riseRate":0.428571,"avgChangeRate":0.093912},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.063229},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.018009},{"month":5,"riseRate":0.833333,"avgChangeRate":0.048413},{"month":6,"riseRate":0.5,"avgChangeRate":-0.094073},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.099771},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007485},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.2127},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.027786},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.069737},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.008174}],"exchange":"NASDAQ","name":"Jasper Therapeutics","nameEN":"Jasper Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jasper Therapeutics(JSPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jasper Therapeutics(JSPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jasper Therapeutics,JSPR,Jasper Therapeutics股票,Jasper Therapeutics股票老虎,Jasper Therapeutics股票老虎国际,Jasper Therapeutics行情,Jasper Therapeutics股票行情,Jasper Therapeutics股价,Jasper Therapeutics股市,Jasper Therapeutics股票价格,Jasper Therapeutics股票交易,Jasper Therapeutics股票购买,Jasper Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jasper Therapeutics(JSPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jasper Therapeutics(JSPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}